Registered report: The CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma

(2014) Hiroki Goto et al.   EUROPEAN JOURNAL OF CANCER

The CD47-SIRP  signalling system: its physiological roles and therapeutic application

(2014) Y. Murata et al.   JOURNAL OF BIOCHEMISTRY

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

(2012) D Kim et al.   LEUKEMIA

Inhibitory signaling through signal regulatory protein-  is not sufficient to explain the antitumor activities of CD47 antibodies

(2012) D. R. Soto-Pantoja et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

(2012) B. Edris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

(2010) Mark P. Chao et al.   CANCER RESEARCH

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

(2009) K. S. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling

(2009) J. B. Maxhimer et al.   Science Translational Medicine